— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.
— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.
— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint brands drove sales of companion animal products higher by 15%.
— International revenue grew 9% on higher sales across key dermatology portfolio and in certain parasiticides, including Simparica and the Revolution/Stronghold franchise, as well as growth across key markets in Western Europe and in China.
— For full-year 2020, the company expects operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income.
— For the full year 2020, the company expects revenue in the range of $6.65-6.8 billion, EPS of $3.53-3.65 and adjusted EPS of $3.90-4.00. The consensus estimates EPS of $4.01 on revenue of $6.7 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
COVID-19 drove retailers up the digital path years ahead than anticipated
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
Adobe (ADBE) sees new tailwinds as virtual shift gathers steam
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related